BERKELEY HEIGHTS, NJ October 8, 2002
- Genta Incorporated (Nasdaq: GNTA) presented an overview of the
companies pipeline, programs and strategic initiatives for future
growth yesterday at the UBS Warburg Life Sciences conference in New
York. The presentation included an update on the continued progress
of Genta's lead anticancer compound, Genasense
TM
, along with a comprehensive overview of the current clinical
trials programs. The Company currently has three randomized
clinical trials that employ Genasense
TM
plus chemotherapy in patients with malignant melanoma,
multiple myeloma, and chronic lymphocytic leukemia. Enrollment into
these trials remains on track, consistent with previous guidance.
The Company also reiterates its confidence that a positive result
from any one of these trials will enable the Company to file a New
Drug Application (NDA) on schedule by the summer of 2003,
consistent with previous guidance. Genasense
TM
has received Orphan Drug designation by the Food and Drug
Administration (FDA) for each of these three indications. The
Company has also received Fast Track designation for melanoma and
myeloma. For a review of the archived audio webcast this
presentation please visit:
http://www.ubswarburg.com/e/homelinks/conferences/index.html
. The audio will be available for 30 days.
About Genasense
TM
Genasense
TM
works by inhibiting the production of Bcl-2, a protein made
by cancer cells that is thought to block chemotherapy-induced cell
death. By reducing the amount of Bcl-2 in cancer cells, Genasense
TM
may enhance the effectiveness of current anticancer
treatments. Genasense
TM
is currently in multiple late-stage randomized clinical
trials including malignant melanoma, multiple myeloma, chronic
lymphocytic leukemia (CLL) and non-small cell lung cancer. Genta is
also conducting additional clinical trials in leukemia, lymphoma,
and cancers of the lung, breast, and prostate.
